InvestorsHub Logo
Followers 45
Posts 5645
Boards Moderated 0
Alias Born 04/05/2015

Re: exwannabe post# 319801

Monday, 10/19/2020 2:30:27 PM

Monday, October 19, 2020 2:30:27 PM

Post# of 705410

But nobody knows if any of those are actually used or needed.



That's the whole point. And as long as nobody knows whether certain proprietary manufacturing techniques are used or needed, then nobody knows what they need to do to replicate the process!

Who is going to invest a few billion and a decade of time and probably fall by the wayside along the way anyway?

It is inordinately difficult for a rival to get where NWBO are by plagiarising techniques and processes, patents or no patents.


Aivita lack the secret sauce, I believe..
Theirs is all autologous, using PBMC-derived DC precursors, plus an autologous self-replicating cancer cell line rather than a lysate. And by using a simple cell line, they will likely fail to pick up all the antigens.

https://aivitabiomedical.com/news/aivita-biomedical-provides-update-of-ongoing-phase-2-glioblastoma-trial-from-year-end-survival-analysis/


It is inordinately difficult for a rival to get where NWBO are by plagiarising and replicating, patents or no patents.
The copycats are not really copycats, imo. And they all appear to lack that certain Je ne sais quoi...

And as for a generic?
Not a chance ever.

The issue is not a source of concern to me at all.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News